Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Baxter Demonstrates Prolonged Half-Life for Hemophilia A Therapy in Mice
 

Baxter Healthcare Corporation reported early progress using mouse models in the development of a longer-acting therapy for hemophilia A. Preclinical data drawn from ongoing research indicate that the half-life of recombinant factor VIII may be extended when it is formulated with recombinant von Willebrand factor. The data were presented at the American Society of Hematology’s 48th Annual Meeting December 9-12, 2006 in Orlando, FL.

The benefit of new factor therapies with an improved half-life is that they would remain active in the body for longer periods, resulting in the need for fewer infusions. Baxter will continue preclinical research until the experimental therapy is ready for clinical studies in patients.               

“We continue to build upon our proven foundation of blood-free recombinant protein processing with the goal of developing recombinant proteins with a longer half-life, which if supported by future clinical trial results, potentially allow for less frequent injections and therefore increase convenience and compliance for patients,” said Peter Turecek, PhD, Senior Director of Preclinical Research and Development for Baxter BioScience.

Source: Baxter Healthcare Corporation news release dated December 11, 2006